Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Total Non-Current Liabilities data on file, last reported at $86.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 5.75% year-over-year to $86.8 million; the trailing twelve-month figure through Mar 2026 stood at $86.8 million (up 5.75% YoY), and the FY2025 full-year result was $94.8 million, up 8.34% from the prior year.
• Total Non-Current Liabilities fell to $86.8 million in Q1 2026, from $94.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $241.1 million in Q3 2023 to a low of $82.1 million in Q1 2025.
• A 5-year average of $106.4 million and a median of $96.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 489.49% in 2022 and plunged 62.64% in 2024, its largest moves.
• Tracing TSHA's Total Non-Current Liabilities over 5 years: stood at $121.2 million in 2022, then retreated by 20.61% to $96.2 million in 2023, then retreated by 9.03% to $87.5 million in 2024, then climbed by 8.34% to $94.8 million in 2025, then dropped by 8.44% to $86.8 million in 2026.
• Business Quant data shows TSHA's Total Non-Current Liabilities at $86.8 million in Q1 2026, $94.8 million in Q4 2025, and $96.0 million in Q3 2025.